Breaking News

Tweet TWEET

Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published

Totality of Data From Three Phase III Trials of The Medicines Company's 
Intravenous Cangrelor Presented and Published 
Champion Trials Pooled Results Presented at European Society of
Cardiology Scientific Session and Published in The Lancet; New Pooled
Analysis Shows Cangrelor Demonstrates Reduction in Angiographic
Complications Compared to Oral Clopidogrel 
AMSTERDAM, THE NETHERLANDS -- (Marketwired) -- 09/03/13 --  The
Medicines Company (NASDAQ: MDCO) today reported presentation and
publication of a pooled analysis of three Phase III clinical trials
of an investigational intravenous (IV) antiplatelet, cangrelor. The
trials compared IV cangrelor to either oral clopidogrel or placebo
for prevention of thrombotic (clotting) complications during and
after percutaneous coronary intervention (PCI). The findings of the
pooled CHAMPION program confirm the results of the CHAMPION PHOENIX
trial presented and published in April 2013.  
This pre-specified, pooled analysis of patient-level data from
CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX was presented
at the European Society of Cardiology today and concurrently
published in The Lancet.  
Professor Christian Hamm, professor of internal medicine and
cardiology and medical director of the Kerckhoff Heart and
Thoraxcenter Bad Nauheim Germany, stated: "This is one of the largest
Phase III programs ever conducted in patients undergoing PCI, an
important consideration when evaluating the strength of the
conclusions in the overall population and in study subgroups."  
The totality of evidence in approximately 25,000 patients undergoing
PCI demonstrates that cangrelor significantly reduced the odds of the
primary composite endpoint of death, myocardial infarction (MI),
ischemia-driven revascularization (IDR) or stent thrombosis (ST) at
48 hours after randomization by 19% (3.8% for cangrelor vs. 4.7% for
control; OR 0.81, 95% CI 0.71-0.91, p=0.0007) and stent thrombosis by
41% (0.5% vs. 0.8%, OR 0.59, 95% CI 0.43-0.80, p=0.0008). "The
findings were consistent across all analyzed subgroups of patients,
including age, geography, diagnosis at presentation, and the choice
of periprocedural anticoagulant, including more than 5,000 patients
treated with bivalirudin," added CHAMPION programme co-chair Dr.
Deepak L. Bhatt, professor of medicine at Harvard Medical School,
chief of cardiology at VA Boston Healthcare System, and senior
physician at Brigham and Women's Hospital. 
"In addition, angiographic complications during the procedure were
significantly reduced by cangrelor with a marked reduction in new or
suspected thrombus, in acute stent thrombosis, and in the need for
bailout glycoprotein IIb/IIIa inhibitor," stated CHAMPION programme
co-chair Dr. Robert A. Harrington, professor of medicine at Stanford
University and chairman of medicine at Stanford. 
The pooled analysis also showed that the incidence of clinically
important major bleeding as measured by GUSTO and TIMI bleeding
scales was not increased with cangrelor. More sensitive measures
showed an increase in bleeding with cangrelor, though there was no
significant difference in the rate of transfusions. There were
significantly more cases of transient dyspnea with cangrelor than
with clopidogrel, a finding that was also observed in the individual
CHAMPION studies. 
"The results of this analysis provide a wealth of data that
intravenous cangrelor reduces thrombotic events and importantly
angiographic complications during the procedure, a totality of
evidence that will have impact on guideline recommendations," said
Professor Phillipe Gabriel Steg, professor of cardiology; director,
Coronary Care Unit Hopital. Bichat-Claude Bernard, Paris, France. 
Simona Skerjanec, PharmD, MBA, Senior Vice President and Innovation
Leader for Antiplatelet Therapies at The Medicines Company confirmed,
"As previously stated we are currently working with the Food and Drug
Administration to progress the US filing and we are on track to file
in Europe as planned in Q4 2013." 
About Cangrelor 
Cangrelor is an investigational agent not approved for commercial use
in any market. Cangrelor, an immediately bioavailable and quickly
reversible intravenous small molecule antiplatelet agent, is in
development to prevent platelet activation and aggregation that leads
to thrombosis in the acute care setting including in patients
undergoing percutaneous coronary intervention (PCI).  
About The Medicines Company
 The Medicines Company (NASDAQ: MDCO)
provides medical solutions to improve health outcomes for patients in
acute and intensive care hospitals worldwide. These solutions
comprise medicines and knowledge that directly impact the survival
and well-being of critically ill patients. The Medicines Company's
website is www.themedicinescompany.com. 
Statements contained in this press release about The Medicines
Company that are not purely historical, and all other statements that
are not purely historical, may be deemed to be forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Without limiting
the foregoing, the words "believes," "anticipates" and "expects" and
similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the Company's actual
results, levels of activity, performance or achievements to be
materially different from those expressed or implied by these
forward-looking statements. Important factors that may cause or
contribute to such differences include whether the Company's products
will advance in the clinical trials process on a timely basis or at
all, whether the Company will make regulatory submissions for product
candidates on a timely basis, whether its regulatory submissions will
receive approvals from regulatory agencies on a timely basis or at
all, whether physicians, patients and other key decision makers will
accept clinical trial results, risks associated with the
establishment of international operations, whether the Company is
able to obtain or maintain patent protection for the intellectual
property relating to the Company's products; and such other factors
as are set forth in the risk factors detailed from time to time in
the Company's periodic reports and registration statements filed with
the Securities and Exchange Commission including, without limitation,
the risk factors detailed in the Company's Quarterly Report on Form
10-Q filed on August 9, 2013, which are incorporated herein by
reference. The Company specifically disclaims any obligation to
update these forward-looking statements.  
Contact: 
Michael Mitchell
The Medicines Company
973-290-6097
michael.mitchell@themedco.com